M. Gordon Joyce, Ph.D.

Dr. Joyce is Chief of the Structural Biology group within the Emerging Infectious Diseases Branch. His group utilizes structural biology with a focus on structure-based vaccine design, small molecule inhibitor design, and viral antigen-antibody structures. The structural biology group utilizes X-ray crystallography and electron microscopy to study and understand immune responses and vaccine-host-virus interactions, leveraging this information to develop medical countermeasures. Most recently, the group has focused on the design and development of a protective pan-sarbecovirus vaccine, and understanding the development of broadly protective immune responses following infection or vaccination.

Dr. Joyce received a B.Sc. (Hons) in Biochemistry from the University of Galway, Ireland in 2001, followed by a Ph.D. in Structural Biology from the University of Leicester, UK in 2006. He then began work on the structural characterization of human immunoreceptors with Dr. Peter Sun in the Laboratory of Immunogenetics at NIH. In 2011, he moved to the NIH’s Vaccine Research Center working with Dr. Gary Nabel, Dr. Peter Kwong, and Dr. John Mascola on the structure-based design of HIV-1, Influenza and RSV vaccine candidates. In 2016, Dr. Joyce joined the Henry M. Jackson Foundation and established the structural biology group at WRAIR.

Dr. Joyce is an author of over 100 peer-reviewed scientific manuscripts focused on vaccine immunogens and monoclonal antibody therapeutics for coronaviruses, flaviviruses, herpesviruses, HIV-1, Influenza, RSV, and hMPV. He is a co-inventor on 27 awarded patents and over 70 patent pending applications, including technology used in at least four of the worldwide vaccines for COVID-19, and the respiratory syncytial virus vaccine approved by the FDA in 2023.

Selected Publications

Chen WH, Hajduczki A, Martinez EJ, Bai H, Matz H, Hill TM, Lewitus E, Chang WC, Dawit L, Peterson CE, Rees PA, Ajayi AB, Golub ES, Swafford I, Dussupt V, David S, Mayer SV, Soman S, Kuklis C, Corbitt C, King J, Choe M, Sankhala RS, Thomas PV, Zemil M, Wieczorek L, Hart T, Duso D, Kummer L, Yan L, Sterling SL, Laing ED, Broder CC, Williams JK, Davidson E, Doranz BJ, Krebs SJ, Polonis VR, Paquin-Proulx D, Rolland M, Reiley WW, Gromowski GD, Modjarrad K, Dooley H, Joyce MG. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity. Nat Commun. 2023 Feb 3;14(1):580. doi: 10.1038/s41467-023-36106-x.PMID: 36737435

Yu J, Thomas PV, Sciacca M, Wu C, Liu J, He X, Miller J, Hachmann NP, Surve N, McMahan K, Jacob-Dolan C, Powers O, Hall K, Barrett J, Hope D, Mazurek CR, Murdza T, Chang WC, Golub E, Rees PA, Peterson CE, Hajduczki A, Chen WH, Martinez EJ, Hussin E, Lange C, Gong H, Matyas GR, Rao M, Suthar M, Boursiquot M, Cook A, Pessaint L, Lewis MG, Andersen H, Bolton DL, Michael NL, Joyce MG, Modjarrad K, Barouch DH. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. Cell Rep Med. 2023 Apr 18;4(4):101018. doi: 10.1016/j.xcrm.2023.101018. Epub 2023 Mar 27.PMID: 37023746

Shrivastava S, Carmen JM, Lu Z, Basu S, Sankhala RS, Chen WH, Nguyen P, Chang WC, King J, Corbitt C, Mayer S, Bolton JS, Anderson A, Swafford I, Terriquez GD, Trinh HV, Kim J, Jobe O, Paquin-Proulx D, Matyas GR, Gromowski GD, Currier JR, Bergmann-Leitner E, Modjarrad K, Michael NL, Joyce MG, Malloy AMW, Rao M. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. NPJ Vaccines. 2023 Mar 18;8(1):43. doi: 10.1038/s41541-023-00638-6.PMID: 36934088

Yu J, Thomas PV, McMahan K, Jacob-Dolan C, Liu J, He X, Hope D, Martinez EJ, Chen WH, Sciacca M, Hachmann NP, Lifton M, Miller J, Powers OC, Hall K, Wu C, Barrett J, Swafford I, Currier JR, King J, Corbitt C, Chang WC, Golub E, Rees PA, Peterson CE, Hajduczki A, Hussin E, Lange C, Gong H, Matyas GR, Rao M, Paquin-Proulx D, Gromowski GD, Lewis MG, Andersen H, Davis-Gardner M, Suthar MS, Michael NL, Bolton DL, Joyce MG, Modjarrad K, Barouch DH. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. Sci Adv. 2022 Nov 25;8(47):eade4433. doi: 10.1126/sciadv.ade4433. Epub 2022 Nov 23.PMID: 36417525

Chen WH, Kim J, Bu W, Board NL, Tsybovsky Y, Wang Y, Hostal A, Andrews SF, Gillespie RA, Choe M, Stephens T, Yang ES, Pegu A, Peterson CE, Fisher BE, Mascola JR, Pittaluga S, McDermott AB, Kanekiyo M, Joyce MG, Cohen JI. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. Immunity. 2022 Nov 8;55(11):2135-2148.e6. doi: 10.1016/j.immuni.2022.10.003. Epub 2022 Oct 27.PMID: 36306784

Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021 Dec 21;37(12):110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 8.PMID: 34919799

Joyce MG, King HAD, Elakhal-Naouar I, Ahmed A, Peachman KK, Macedo Cincotta C, Subra C, Chen RE, Thomas PV, Chen WH, Sankhala RS, Hajduczki A, Martinez EJ, Peterson CE, Chang WC, Choe M, Smith C, Lee PJ, Headley JA, Taddese MG, Elyard HA, Cook A, Anderson A, McGuckin Wuertz K, Dong M, Swafford I, Case JB, Currier JR, Lal KG, Molnar S, Nair MS, Dussupt V, Daye SP, Zeng X, Barkei EK, Staples HM, Alfson K, Carrion R, Krebs SJ, Paquin-Proulx D, Karasavva N, Polonis VR, Jagodzinski LL, Amare MF, Vasan S, Scott PT, Huang Y, Ho DD, de Val N, Diamond MS, Lewis MG, Rao M, Matyas GR, Gromowski GD, Peel SA, Michael NL, Bolton DL, Modjarrad K. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Sci Transl Med. 2022 Feb 16;14(632):eabi5735. doi: 10.1126/scitranslmed.abi5735. Epub 2022 Feb 16.PMID: 34914540

Dussupt V, Sankhala RS, Mendez-Rivera L, Townsley SM, Schmidt F, Wieczorek L, Lal KG, Donofrio GC, Tran U, Jackson ND, Zaky WI, Zemil M, Tritsch SR, Chen WH, Martinez EJ, Ahmed A, Choe M, Chang WC, Hajduczki A, Jian N, Peterson CE, Rees PA, Rutkowska M, Slike BM, Selverian CN, Swafford I, Teng IT, Thomas PV, Zhou T, Smith CJ, Currier JR, Kwong PD, Rolland M, Davidson E, Doranz BJ, Mores CN, Hatziioannou T, Reiley WW, Bieniasz PD, Paquin-Proulx D, Gromowski GD, Polonis VR, Michael NL, Modjarrad K, Joyce MG, Krebs SJ. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nat Immunol. 2021 Dec;22(12):1503-1514. doi: 10.1038/s41590-021-01068-z. Epub 2021 Oct 29.PMID: 34716452

Wuertz KM, Barkei EK, Chen WH, Martinez EJ, Lakhal-Naouar I, Jagodzinski LL, Paquin-Proulx D, Gromowski GD, Swafford I, Ganesh A, Dong M, Zeng X, Thomas PV, Sankhala RS, Hajduczki A, Peterson CE, Kuklis C, Soman S, Wieczorek L, Zemil M, Anderson A, Darden J, Hernandez H, Grove H, Dussupt V, Hack H, de la Barrera R, Zarling S, Wood JF, Froude JW, Gagne M, Henry AR, Mokhtari EB, Mudvari P, Krebs SJ, Pekosz AS, Currier JR, Kar S, Porto M, Winn A, Radzyminski K, Lewis MG, Vasan S, Suthar M, Polonis VR, Matyas GR, Boritz EA, Douek DC, Seder RA, Daye SP, Rao M, Peel SA, Joyce MG, Bolton DL, Michael NL, Modjarrad K. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines. 2021 Oct 28;6(1):129. doi: 10.1038/s41541-021-00392-7.PMID: 34711815

King HAD, Joyce MG, Lakhal-Naouar I, Ahmed A, Cincotta CM, Subra C, Peachman KK, Hack HR, Chen RE, Thomas PV, Chen WH, Sankhala RS, Hajduczki A, Martinez EJ, Peterson CE, Chang WC, Choe M, Smith C, Headley JA, Elyard HA, Cook A, Anderson A, Wuertz KM, Dong M, Swafford I, Case JB, Currier JR, Lal KG, Amare MF, Dussupt V, Molnar S, Daye SP, Zeng X, Barkei EK, Alfson K, Staples HM, Carrion R, Krebs SJ, Paquin-Proulx D, Karasavvas N, Polonis VR, Jagodzinski LL, Vasan S, Scott PT, Huang Y, Nair MS, Ho DD, de Val N, Diamond MS, Lewis MG, Rao M, Matyas GR, Gromowski GD, Peel SA, Michael NL, Modjarrad K, Bolton DL. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2106433118. doi: 10.1073/pnas.2106433118.PMID: 34470866

Link to all publications